New drug cocktail shows promise in shrinking kidney tumors before surgery
NCT ID NCT07571551
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether giving two drugs—toripalimab and lenvatinib—before and after surgery can improve outcomes for people with clear cell renal cell carcinoma. The study enrolls 75 patients with different stages of kidney cancer. Participants receive the drugs for 12 weeks before surgery, then continue treatment afterward based on their surgical results. The main goal is to see how many patients have a major reduction in viable tumor cells after the pre-surgery treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
toripalimab and lenvatinib
What this could lead to
If successful, this combination could become a new standard treatment to shrink kidney tumors before surgery and reduce the chance of cancer coming back afterward.
What could go wrong
This is an early phase 2 trial with only 75 patients, so results may not apply to everyone. The drugs can cause serious side effects like high blood pressure, fatigue, and immune-related inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••